晚期NSCLC一线免疫治疗合适的持续时间及其预测因素OA

First-line immunotherapy for advanced non-small cell lung cancer(NSCLC)shows significant survival benefits in patients without driver mutations,but the optimal duration of treatment remains controversial.Some studies sup-port limiting immunotherapy to 2 years,arguing that longer treatment does not bring additional survival benefits;while other studies believe that treatment should continue until disease progression to maximize survival benefits.This article systemati-cally reviews the current research progress on the duration of immunotherapy and discusses the potential predictive value of biomarkers such as circulating tumor DNA(ctDNA),the best efficacy response,and programmed cell death ligand 1(PD-L1)expression levels in individualized treatment decisions.More prospective studies,especially biomarker-driven trials,are still needed to clarify the optimal duration of treatment and establish an individualized treatment strategy based on multidimen-sional indicators.